Patents Examined by Sharmila Gollamudi
-
Patent number: 7595345Abstract: The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon-linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: GrantFiled: November 16, 2004Date of Patent: September 29, 2009Assignee: Eli Lilly and CompanyInventors: Emilio Enrique Bunel, Robert Peter Gajewski, Charles David Jones, Jianliang Lu, Sunil Nagpal, Tianwei Ma, Ying Kwong Yee
-
Patent number: 7589106Abstract: An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-administer 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.Type: GrantFiled: September 26, 2007Date of Patent: September 15, 2009Assignee: Eagle Pharmaceuticals, Inc.Inventor: Nageswara R. Palepu
-
Patent number: 7579021Abstract: Matrix controlled diffusion drug delivery systems based on one or more silicon-containing monomers of the general formula: wherein L, X?, n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.Type: GrantFiled: September 27, 2006Date of Patent: August 25, 2009Assignee: Bausch & Lomb IncorporatedInventors: Jay F. Kunzler, Derek Schorzman, Daniel M. Ammon, Jr.
-
Patent number: 7550512Abstract: The present invention provides a polyethylene glycol derivative having sugar residue-containing side chains and carboxyl group-containing side chains, and a method of preparing the same. The present invention also provides a carrier for drug delivery systems and a carrier for gene transfer, both comprising the polyethylene glycol derivative.Type: GrantFiled: June 3, 2004Date of Patent: June 23, 2009Assignees: Keio University, NOF CorporationInventors: Toshinori Sato, Yoshiyuki Koyama, Tetsuji Yamaoka
-
Patent number: 7541472Abstract: Compounds of formula I are described: along with compositions thereof, methods of use thereof (particularly as fungicides), and methods of making the same.Type: GrantFiled: May 24, 2005Date of Patent: June 2, 2009Assignee: Cropsolution, Inc.Inventors: Richard Anderson, Shy-Fuy Lee, Vivian Du, Takeo Hokama, Rafael Oey, Patricia Arakaki
-
Patent number: 7531575Abstract: Described is a rational design of therapeutic and/or prophylactic methods of treating conditions characterized by aberrant or otherwise unwanted microglial cell functioning and rational design methods for treating a range of neurological disorders which are characterized by nitric oxide induced neuronal damage.Type: GrantFiled: October 31, 2003Date of Patent: May 12, 2009Assignee: Eberhard-Karls-Universität TübinginInventors: Michael Weller, Wolfgang Wick, Jörg Wischhusen, Michael Platten
-
Patent number: 7531529Abstract: The present invention relates to imidazole derivatives of formula I wherein R1, R2, R3 and R4 are described hereinabove. These compounds can be used in the treatment or prevention of mGluR5 receptor mediated disorders. These compounds are useful, inter alia, in the treatment of genitourinary diseases.Type: GrantFiled: December 22, 2004Date of Patent: May 12, 2009Assignee: Roche Palo Alto LLCInventors: Bernd Buettelmann, Simona Maria Ceccarelli, Georg Jaeschke, Sabine Kolczewski, Richard Hugh Philip Porter, Eric Vieira, Anthony P. D. W. Ford, Yu Zhong
-
Patent number: 7524882Abstract: A class of benzodihydrofuran compounds having the structure of formula (I) below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, such as atherosclerosis.Type: GrantFiled: July 25, 2003Date of Patent: April 28, 2009Assignee: Merck & Co., Inc.Inventors: Guo Q. Shi, Yong Zhang
-
Patent number: 7449494Abstract: The present invention is directed to a series of new cationic polymeric materials and a process for their use as moisturizing agents on skin. The polymers of the invention are made by the reaction of dimethyl ethanolamine, and tetra 2-hydroxyalkyl ethylene diamne with di-chloro glycerin in water.Type: GrantFiled: October 6, 2004Date of Patent: November 11, 2008Assignee: SurfaTech CorporationInventor: Anthony J. O'Lenick, Jr.
-
Patent number: 7323184Abstract: The present invention relates to methods and compositions for inhibiting scar formation on wound region. In certain embodiments, the methods include administering an alkalinization agent in combination with hyaluronic acid to a wound site to reduce the formation of scars at the wound site. Suitable alkalization agents include sodium bicarbonate, sodium hydroxide and potassium hydroxide.Type: GrantFiled: June 28, 2006Date of Patent: January 29, 2008Assignee: Healagenics, Inc.Inventors: Mary Ellen Freddo, Ki Chang Keum, Naechoon Yoo, Won Min Yoo
-
Patent number: 7288533Abstract: A topical applications is used to treat and prevent the spread of nail infections or onychomycosis caused by bacteria, fungi and other pathogens. The topical application has a composition that comprises, as an active ingredient, at least one species selected from the group consisting of 2,2?-(alkyldioxy) bis-(alkyl-1,3,2-dioxaborinane) and 2,2?-oxybis(alkyl-1,3,2-dioxaborinane). More specifically, the composition comprises, as an active ingredient, at least one member selected from the group consisting of 2,2?-(1-methyltrimethylene dioxy) bis-(4-methyl-1,3,2-dioxaborinane) and 2,2?-oxybis (4,4,6-trimethyl-1,3,2-dioxaborinane).Type: GrantFiled: December 29, 2004Date of Patent: October 30, 2007Inventor: James Edward Brehove
-
Patent number: 7195769Abstract: A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation caused by presence of Isoniazid. Rifampicin and/or Isoniazid may be present in delayed release and/or extended release form such that minimal amount of the drug is dissolved between pH 1 and 4. preferably delayed release of Rifampicin and/or Isoniazid is achieved by treating the drugs with pH sensitive polymers.Type: GrantFiled: April 10, 2001Date of Patent: March 27, 2007Assignee: Panacea Biotec LimitedInventors: Amarjit Singh, Rajesh Jain
-
Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
Patent number: 7135190Abstract: A water soluble, biodegradable reverse thermal gelation system comprising a mixture of at least two types of tri-block copolymer components is disclosed. The tri-block copolymer components are made of a hydrophobic biodegradable polyester A-polymer block and a hydrophilic polyethylene glycol B-polymer block. The drug release and gel matrix erosion rates of the biodegradable reverse thermal gelation system may be modulated by various parameters such as the hydrophobic/hydrophilic component contents, polymer block concentrations, molecular weights and gelation temperatures, and weight ratios of the tri-block copolymer components in the mixture.Type: GrantFiled: January 29, 2004Date of Patent: November 14, 2006Assignee: Macromed, Inc.Inventors: Ai-Zhi Piao, Chung Shih -
Patent number: 7078045Abstract: A pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis, which comprises 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and dimethyl-4,4?-dimethoxy-5,6,5?,6?-dimethylene dioxybiphenyl-2,2?-dicarboxylate (DDB) as major components, is provided. The ratio of oltipraz and DDB of said composition is preferably 25:0–25, more preferably 5:0.1–5, particularly preferably 5:1. Oltipraz/DDB formulations according to the present invention exhibit surprisingly good effect on the treatment and prevention of liver fibrosis and cirrhosis and are safe drugs that have low toxicity in the human body.Type: GrantFiled: March 2, 2001Date of Patent: July 18, 2006Assignee: Sang-Geon KimInventors: Sang-Geon Kim, Keon-Wook Kang
-
Patent number: 7067149Abstract: The invention concerns an improved multiparticulate tablet disintegrating in the mouth in contact with saliva in less than 40 seconds. The invention is characterized in that it is based on particles of coated active principle, said particles having intrinsic compression properties and a mixture of carriers, the proportion of carrier mixture relative to coated active principle particles being 0.4 to 6 parts by weight, the carrier mixture comprising: a disintegrating agent; a diluting soluble agent with binding properties; a lubricant; a permeabilizing agent; and advantageously lubricants, sweeteners, flavoring and coloring agents, the proportion of disintegrating agent and soluble agent relative to the tablet mass being 1 to 15% by weight for the former and 30 to 90% by weight for the latter.Type: GrantFiled: November 3, 1999Date of Patent: June 27, 2006Assignee: EthypharmInventors: Charles Chauveau, Jean-Marc Zuccarelli, Nourredine Nouri, Maryvonne Barbero
-
Patent number: 6730320Abstract: An antibiotic product, in particular a tetracycline, such as doxycycline, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: December 20, 2001Date of Patent: May 4, 2004Assignee: Advancis Pharmaceutical Corp.Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
-
Patent number: 6627698Abstract: A batch steam distillation process removes volatile siloxane oligomers from an emulsion containing siloxane polymers and volatile siloxane oligomers prepared by emulsion polymerization of volatile siloxane oligomers. In one embodiment, emulsions stripped of volatile siloxane oligomers are re-catalyzed to initiate condensation polymerization. In another embodiment, clear emulsions stripped of volatile siloxane oligomers are provided even though an antifoam is used in the stripping process.Type: GrantFiled: February 13, 2001Date of Patent: September 30, 2003Assignee: Dow Corning CorporationInventors: Burt Michael Wrolson, Brett Lee Zimmerman
-
Patent number: RE40045Abstract: Pharmaceutical compositions comprising effective amounts of salmeterol (and a physiologically acceptable salt thereof) and fluctuations propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.Type: GrantFiled: September 3, 2004Date of Patent: February 5, 2008Assignee: Glaxo Group LimitedInventor: James B. D. Palmer